Director Of Operations at Duo Oncology - Pittsburgh, PA, US
CEO and Co-Founder
Contact Sam Rothstein
Right now, 60-80% of patients show little response to standard immunotherapy or chemotherapy. Duo Oncology plans to transform patient outcomes with a new type of nanotherapy.